Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
574 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06064500 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | approved for marketing | — | — | AmgenINDUSTRY | 4 | Mar 10, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT04504513 | Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer | approved for marketing | — | — | G1 Therapeutics, Inc.INDUSTRY | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Jun 19, 2020 | clinicaltrials |
| NCT03089658 | Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) | approved for marketing | — | — | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2025source: clinicaltrials